StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy
Revolution Medicines (Nasdaq: RVMD) appeared to have the makings of another strong stock surge this past week when the FDA approved the company’s historic oral therapy Rasonque (daraxonrasib), the first RAS inhibitor to be...
From Images to Data
Read NowQuantitative spatial biology is coming of age. The desire to learn beyond the surface has always been present but now the ability to deepen that knowledge with real data is catching up. High-plex...
Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer
Aprea Therapeutics is accelerating enrollment in its ongoing Phase I trial of its targeted cancer therapy APR-1051, one of the precision oncology drug developer’s two lead programs, and expanding its indications under study after...
The Next Wave of ADC Innovation: The Science Behind Dual-Payload Bioconjugates
Register Now
Cindy Cheng Executive Director, Head of New Technology DiscoveryWuXi XDC View Bio
Panelist ...
Myotis Bat Genomes Reveal How They Fight Viruses, Cancer, and Cellular Damage
Bats are among the most diverse mammalian species—second only to rodents—and are anomalies in the mammalian world: they fly, have long lifespans for their size, and rarely get cancer.
Scientists now provide insights into these...
Expanded Synthetic Promoter Library Introduced to Boost Biomanufacturing Operations
SynGenSys, based in Sheffield, U.K., reports that it has introduced its CHO.SET® 2.0 synthetic gene promoter system to improve protein production in CHO (Chinese Hamster Ovary) cells.
Andy Racher, PhD, CEO, SynGenSys Developed de novo...
Small Molecules, Big Expectations: How CDMOs Are Helping Sponsors Navigate Complexity, Speed, Scale-Up, and...
Small molecules continue to play a major part in pharmaceutical development, but increasing molecular complexity, accelerated timelines, and evolving manufacturing and regulatory requirements are creating new challenges for the industry.In this GEN Podcast –...
From Models to Agents: The Next Phase of AI Adoption in Molecular Discovery
In recent years, the artificial intelligence (AI) conversation has been dominated by increasingly capable large language models. Every few months, models improve on mathematical reasoning and coding benchmarks, while inference costs drop. Since 2025,...
DeepCyte Launches Single-Cell Metabolomic Reference Atlas of Drug Toxicity Mechanisms
DeepCyte launched the DeeTox Atlas, a single-cell metabolomic reference atlas of drug toxicity mechanisms. Enterprise pilot programs with global pharmaceutical companies are expected to begin in the coming months.
DeeTox Atlas is described as a...
Is Targeted Protein Degradation the “Break” Neurology Needs?
Register Now
Angela M. Cacace, PhD Chief Scientific OfficerArvinas View Bio
Panelist ...
